Portal:CPTAC

From WikiPathways

(Difference between revisions)
Jump to: navigation, search
Line 9: Line 9:
}}
}}
-
<div style="float:left; width:72%"> <!-- This width add to the the margin below to equal 99%-->
+
<div style="float:left; width:68%"> <!-- This width add to the the margin below to equal 99%-->
 +
 
{{{{FULLPAGENAME}}/box-normal
{{{{FULLPAGENAME}}/box-normal
|<!-- TITLE OF BOX -->
|<!-- TITLE OF BOX -->
Line 22: Line 23:
</div>
</div>
-
<div style="float:right; width:27%"> <!-- This margin should be right of the above -->
+
<div style="float:right; width:31%"> <!-- This margin should be right of the above -->
{{{{FULLPAGENAME}}/box-normal
{{{{FULLPAGENAME}}/box-normal

Revision as of 18:04, 3 October 2017

edit  

CPTAC Pathways

Welcome to the CPTAC Pathway Portal

This portal highlights pathway content relevant to the Clinical Proteomic Tumor Analysis Consortium (CPTAC).

The National Cancer Institute, part of the National Institutes of Health, announced the launch of a Clinical Proteomic Tumor Analysis Consortium in August 2011. CPTAC is a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of cancer through the application of robust, quantitative, proteomic technologies and workflows. The overarching goal of CPTAC is to improve our ability to diagnose, treat and prevent cancer. To achieve this goal in a scientifically rigorous manner, the NCI launched CPTAC to systematically identify proteins that derive from alterations in cancer genomes and related biological processes, and provide this data with accompanying assays and protocols to the public.

The pathways included in this portal have been organized into classic cancer hallmark categories, based on the different biological capabilities acquired during the multistep development of human tumors. To read more, see Hallmarks of cancer: the next generation, Hanahan and Weinberg, Cell 2011.

edit  

Cancer Hallmark Categories

Sustaining proliferative signaling

MET in type 1 papillary renal cell carcinoma (Homo sapiens)

Image does not exist
MET in type 1 papillary renal cell carcinoma
Evading growth suppressors

Tumor suppressor activity of SMARCB1 (Homo sapiens)

Image does not exist
Tumor suppressor activity of SMARCB1
Activating invasion and metastasis

MFAP5-mediated ovarian cancer cell motility and invasiveness (Homo sapiens)

Image does not exist
MFAP5-mediated ovarian cancer cell motility and invasiveness
Enabling replicative immortality

Notch signaling (Homo sapiens)

Image does not exist
Notch signaling
Inducing angiogenesis

Angiogenesis (Homo sapiens)

Image does not exist
Angiogenesis
Resisting cell death

PI3K-AKT-mTOR signaling and therapeutic opportunities in prostate cancer (Homo sapiens)

Image does not exist
PI3K-AKT-mTOR signaling and therapeutic opportunities in prostate cancer
Deregulating cellular energetics

Target of rapamycin signaling (Homo sapiens)

Image does not exist
Target of rapamycin signaling
Genome instability and mutation

DNA IR-double strand breaks and cellular response via ATM (Homo sapiens)

Image does not exist
DNA IR-double strand breaks and cellular response via ATM
Tumor promoting inflammation

IL1 signaling (Homo sapiens)

Image does not exist
IL1 signaling
Avoiding immune destruction

Altered glycosylation of MUC1 in tumor microenvironment (Homo sapiens)

Image does not exist
Altered glycosylation of MUC1 in tumor microenvironment
Therapeutics

Cancer immunotherapy by CTLA4 blockade (Homo sapiens)

Image does not exist
Cancer immunotherapy by CTLA4 blockade

edit  

Featured Pathways

edit  

Pathway Curation

On this page you see rotating displays of hallmark and featured pathways. Where did these pathways come from? They came from people like you! The CPTAC set of pathways can be edited, fixed and added to using the pathway drawing and annotation tools here at WikiPathways.

Getting Started

Resources

Curation projects

edit  

Useful Links

Personal tools